Etern

Based in Shanghai, China, and founded in 2018, Etern BioPharma (Shanghai) Co. , Ltd. , trading as Etern, operates as a drug developer mainly engaged in the research and development of small molecule drugs targeting protein liquid-liquid phase separation. Jidong Zhu, the co-founder of the company, has worked at Novartis and served as an independent principal investigator in the Chinese Academy of Sciences for 7 years.

In October 2021, it won the Excellent Enterprise Award of the 10th China Innovation & Entrepreneurship Competition Biomedical Section. In June 2026, Etern raised a Series B2 funding led by Jinkong Fund Management. The company provides innovative drugs for tumor targets and related solutions for tumor treatment. The products include the SRC homology-2 domain-containing phosphatase 2 (SHP2) allosteric inhibitor ET0038 and protein liquid-liquid phase separation (LLPS) technology platform.

The company adopts structural biology and molecular biology mechanisms. The company generates revenue by developing small‑molecule therapeutics through its LLPS-based drug discovery platform and by providing related drug research and development services. The Series B2 funding raised in June 2026 will be used to focuses on the company's core innovative drug pipeline advancement, R&D platform upgrades, and commercialization. In the future, the company will continue to delve into cutting-edge LLPS underlying technologies, accelerate the global clinical development and registration of its core pipelines, and continuously produce world-first-in-class original drugs.

At the same time, it will deepen the technological synergy between LLPS and AI-driven drug development, based on rigorous medical drug research and development, and expand into the consumer healthcare sector to precisely meet the public's increasingly sophisticated needs for high-end anti-aging and health maintenance.